Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Portfolio Pulse from Vandana Singh
Silexion Therapeutics Corp. (NASDAQ:SLXN) stock surged over 21% in pre-market trading following promising Phase 2 trial results for its pancreatic cancer treatment, LODER. The trial showed a 56% objective response rate, with a 67% rate in previously non-resectable tumors becoming resectable. The company is also developing SIL-204, targeting a broader range of KRAS mutations.
September 24, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silexion Therapeutics' stock rose significantly due to positive Phase 2 trial results for its pancreatic cancer treatment, LODER. The trial showed a high objective response rate and increased tumor resectability, enhancing surgical options for patients.
The significant increase in stock price is directly linked to the promising trial results for LODER, which showed a high objective response rate and potential for increased tumor resectability. This news is critical for investors as it indicates potential future success and marketability of the treatment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100